Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials.

The American journal of gastroenterology - 1 Jun 2018

Zamor Philippe J, Vierling John, Ghalib Reem, Luketic Velimir, Ravendhran Natarajan, Balart Luis, Robertson Michael, Hwang Peggy, Hanna George J, Nguyen Bach-Yen, Barr Eliav, Talwani Rohit, Pearlman Brian

Abstract excerpt

OBJECTIVES: Although direct-acting antiviral regimens have dramatically improved the treatment of hepatitis C virus (HCV) infection, there is some evidence that black race may be an independent predictor of treatment failure. We report a retrospective analysis of black participants receiving elbasvir/grazoprevir (EBR/GZR) in nine phase 2/3 clinical trials. METHODS: Black participants with chronic HCV genotype 1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzofurans
Share to Clinical Trials, Phase II as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase III as Topic

Share to Drug Combinations

Share to Imidazoles

Share to Quinoxalines

Share to Sustained Virologic Response

Share to Treatment Failure

Source

Identifiers

PMID: 29695828
DOI: 10.1038/s41395-018-0053-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials.PMID 29695828Read ↗

Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*.Semantic proximity Read ↗

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.Semantic proximity Read ↗

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.Semantic proximity Read ↗

Hepatitis C-positive Black patients develop hepatocellular carcinoma at earlier stages of liver disease and present with a more aggressive phenotype.Semantic proximity Read ↗

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.Semantic proximity Read ↗

Boceprevir for untreated chronic HCV genotype 1 infection.Semantic proximity Read ↗

Ethnic epidemiological profiles and antiviral therapy among patients infected with hepatitis C virus genotype 4: a multicenter study from Belgium.Semantic proximity Read ↗

Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.Semantic proximity Read ↗

No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients.Semantic proximity Read ↗

Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis.Semantic proximity Read ↗

Hepatitis C genotype 4 response rate to pegylated interferon and ribavirin treatment in Belgium is similar to genotype 1.Semantic proximity Read ↗

Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.